Evidence map›Paper›PMID 38741227›Full record

ReviewJournal of Crohn's & colitis2024

Management of Colorectal Neoplasia in IBD Patients: Current Practice and Future Perspectives.

Monica E W Derks, Maarten Te Groen, Lisa M A van Lierop, Sanjay Murthy, David T Rubin, Talat Bessissow, Iris D Nagtegaal, Willem A Bemelman, Lauranne A A P Derikx, Frank Hoentjen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Crohn's & colitis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. New Technologies for IBD Endoscopy.Journal of clinical medicine · 2026
    Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Monica E W DerksInflammatory Bowel Disease Center, Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-4247-3987
Maarten Te GroenInflammatory Bowel Disease Center, Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-9323-1486
Lisa M A van LieropInflammatory Bowel Disease Center, Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands.
Sanjay MurthyOttawa Hospital IBD Center and Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
David T RubinUniversity of Chicago Medicine Inflammatory Bowel Disease Center, University of Chicago, Chicago, IL, USA.ORCID 0000-0001-5647-1723
Talat BessissowDivision of Gastroenterology, Department of Medicine, McGill University Health Center, Montreal, QC, Canada.ORCID 0000-0003-2610-1910
Iris D NagtegaalDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Willem A BemelmanDepartment of Surgery, Amsterdam University Medical Center, AMC, Amsterdam, The Netherlands.
Lauranne A A P DerikxDepartment of Gastroenterology, Erasmus Medical Center, Rotterdam, The Netherlands.
Frank HoentjenInflammatory Bowel Disease Center, Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease [IBD] patients are at increased risk of developing colorectal neoplasia [CRN]. In this review, we aim to provide an up-to-date overview and future perspectives on CRN management in IBD. Advances in endoscopic surveillance and resection techniques have resulted in a shift towards endoscopic management of neoplastic lesions in place of surgery. Endoscopic treatment is recommended for all CRN if complete resection is feasible. Standard [cold snare] polypectomy, endoscopic mucosal resection and endoscopic submucosal dissection should be performed depending on lesion complexity [size, delineation, morphology, surface architecture, submucosal fibrosis/invasion] to maximise the likelihood of complete resection. If complete resection is not feasible, surgical treatment options should be discussed by a multidisciplinary team. Whereas [sub]total and proctocolectomy play an important role in management of endoscopically unresectable CRN, partial colectomy may be considered in a subgroup of patients in endoscopic remission with limited disease extent without other CRN risk factors. High synchronous and metachronous CRN rates warrant careful mucosal visualisation with shortened intervals for at least 5 years after treatment of CRN.

Indexed as

ColonoscopyColorectal NeoplasmsInflammatory Bowel DiseasesColectomyEndoscopic Mucosal ResectionHumansRisk Factorscolorectal cancercolorectal neoplasiaCrohn’s diseaseInflammatory bowel diseasesurveillanceulcerative colitis

Identifiers

PMID38741227
PMCPMC11479698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.